Story perspectives
FDA's Priority Review Could Transform HER2 Breast Cancer Treatment
10/6/2025
1 of 1
Story summary
- The FDA has granted priority review for Enhertu and Perjeta, potentially redefining first-line treatment for HER2-positive breast cancer.
- The American Cancer Society projects 317,000 new invasive breast cancers and about 42,170 deaths in the U.S. in 2025.
- Dr. Nan Chen notes a 43% decline in breast cancer death rates since 1989, linked to earlier detection and improved treatments.
